MIA: A Protein with Potential as A Drug Target Or Biomarker (G8190)

Target Name: MIA

NCBI ID: G8190

Content of Review Report on MIA Target / Biomarker

MIA

MIA: A Protein with Potential as A Drug Target Or Biomarker

MIA, short for Missing Interactions, is a protein that is expressed in various tissues throughout the body. It is a key regulator of cell-signaling pathways and has been implicated in a number of diseases, including cancer. In recent years, researchers have been interested in studying MIA as a potential drug target or biomarker due to its unique structure and biology.

MIA was first identified in the 1990s by researchers at the University of California, San Diego. They found that MIA was a highly conserved protein that was expressed in many different tissues, including brain, heart, and muscle. The protein was also known for its ability to interact with a variety of molecules, including transcription factors, RNA-binding proteins, and protein kinases.

Since its initial discovery, researchers have continued to study MIA's biology and explore its potential as a drug target or biomarker. One of the main reasons for this interest is MIA's unique structure. MIA is a transmembrane protein, which means that it spans the cell membrane and extends into the cytoplasm. This unique structure allows MIA to interact with a wide variety of molecules on the cell surface, making it a promising target for drugs that can modulate cell signaling pathways.

Another reason for the interest in MIA is its involvement in a number of diseases. For example, MIA has been implicated in the development and progression of many types of cancer, including breast, ovarian, and prostate cancer. Additionally, MIA has been linked to a number of other diseases, including cardiovascular disease, neurodegenerative diseases, and autoimmune disorders. This makes it an attractive target for drugs that can improve treatment outcomes for these conditions.

In addition to its potential as a drug target, MIA has also been studied as a biomarker. This is because its expression has been shown to be regulated by a wide variety of factors, including genetic and environmental factors. This makes MIA an attractive candidate for use as a biomarker for a variety of diseases, including cancer, cardiovascular disease, and neurodegenerative disorders.

One of the challenges in studying MIA as a drug target or biomarker is its complex biology. MIA is involved in many different signaling pathways, and it is difficult to fully understand how it interacts with these pathways. Additionally, MIA is a protein that is expressed in many different tissues, which makes it difficult to study its effects in a specific context.

Despite these challenges, researchers continue to be interested in studying MIA as a drug target or biomarker. Because of its unique structure and biology, MIA has the potential to be a valuable tool for the development of new treatments for a wide variety of diseases. As research continues, it is likely that the full potential of MIA will be revealed, and it will be an important player in the field of pharmacology.

Protein Name: MIA SH3 Domain Containing

Functions: Elicits growth inhibition on melanoma cells in vitro as well as some other neuroectodermal tumors, including gliomas

The "MIA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets